Ardelyx/$ARDX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ardelyx
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ticker
$ARDX
Sector
Primary listing
Employees
489
Headquarters
Website
Ardelyx Metrics
BasicAdvanced
$1.5bn
-
-$0.24
0.66
-
Price and volume
Market cap
$1.5bn
Beta
0.66
52-week high
$8.40
52-week low
$3.49
Average daily volume
3.9m
Financial strength
Current ratio
3.485
Quick ratio
2.929
Long term debt to equity
156.517
Total debt to equity
157.533
Interest coverage (TTM)
-1.29%
Profitability
EBITDA (TTM)
-34.049
Gross margin (TTM)
74.56%
Net profit margin (TTM)
-13.58%
Operating margin (TTM)
-8.75%
Effective tax rate (TTM)
-0.20%
Revenue per employee (TTM)
$870,000
Management effectiveness
Return on assets (TTM)
-5.11%
Return on equity (TTM)
-39.46%
Valuation
Price to revenue (TTM)
3.549
Price to book
10.39
Price to tangible book (TTM)
10.39
Price to free cash flow (TTM)
-40.475
Free cash flow yield (TTM)
-2.47%
Free cash flow per share (TTM)
-0.154
Growth
Revenue change (TTM)
18.24%
Earnings per share change (TTM)
5.23%
3-year revenue growth (CAGR)
89.29%
10-year revenue growth (CAGR)
37.16%
3-year earnings per share growth (CAGR)
-13.68%
10-year earnings per share growth (CAGR)
-18.56%
What the Analysts think about Ardelyx
Analyst ratings (Buy, Hold, Sell) for Ardelyx stock.
Ardelyx Financial Performance
Revenues and expenses
Ardelyx Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs